Organon & Co. (NYSE:OGN) Given New $24.00 Price Target at Barclays

Organon & Co. (NYSE:OGN) had its price objective reduced by stock analysts at Barclays from $26.00 to $24.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Barclays‘s price target would indicate a potential upside of 50.30% from the stock’s previous close.

Other research analysts have also recently issued reports about the company. Morgan Stanley decreased their target price on Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating for the company in a research note on Friday. TD Cowen raised Organon & Co. to a “hold” rating in a research note on Wednesday, January 15th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $20.80.

Organon & Co. Trading Down 2.2 %

NYSE:OGN traded down $0.35 during mid-day trading on Friday, hitting $15.97. The company had a trading volume of 476,576 shares, compared to its average volume of 2,688,068. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70. Organon & Co. has a fifty-two week low of $13.87 and a fifty-two week high of $23.10. The firm has a market cap of $4.11 billion, a P/E ratio of 3.17, a P/E/G ratio of 0.83 and a beta of 0.76. The business’s fifty day moving average is $15.34 and its two-hundred day moving average is $17.53.

Organon & Co. (NYSE:OGN) last issued its earnings results on Thursday, February 13th. The company reported $0.83 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.09). Organon & Co. had a net margin of 20.30% and a return on equity of 644.70%. As a group, research analysts expect that Organon & Co. will post 3.82 earnings per share for the current year.

Institutional Investors Weigh In On Organon & Co.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. SG Americas Securities LLC increased its position in shares of Organon & Co. by 161.1% in the third quarter. SG Americas Securities LLC now owns 22,689 shares of the company’s stock valued at $434,000 after acquiring an additional 14,000 shares during the last quarter. SeaCrest Wealth Management LLC increased its position in shares of Organon & Co. by 32.7% during the 3rd quarter. SeaCrest Wealth Management LLC now owns 16,218 shares of the company’s stock worth $310,000 after purchasing an additional 3,999 shares during the last quarter. nVerses Capital LLC bought a new stake in shares of Organon & Co. during the 3rd quarter worth approximately $260,000. Trust Co. of Vermont boosted its holdings in shares of Organon & Co. by 109.4% in the 3rd quarter. Trust Co. of Vermont now owns 2,626 shares of the company’s stock valued at $50,000 after buying an additional 1,372 shares during the last quarter. Finally, Blue Trust Inc. increased its holdings in Organon & Co. by 217.5% during the third quarter. Blue Trust Inc. now owns 3,661 shares of the company’s stock worth $76,000 after buying an additional 2,508 shares during the last quarter. 77.43% of the stock is owned by institutional investors.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.